Targeting MET Exon 14 Skipping Mutations in NSCLC

VISION Trial Shows Favorable Tolerability of Tepotinib in NSCLC

Mark A. Socinski, MD, discusses the safety profile of tepotinib that was observed in the VISION trial of patients with advanced or metastatic non–small cell lung cancer with MET exon 14 skipping mutations.

Challenges for Following NCCN Guidelines for MET Inhibitors in NSCLC

Martin Dietrich, MD, PhD, discusses the National Comprehensive Cancer Network guidelines for using MET inhibitors in patients with non–small cell lung cancer and their impact on sequencing therapies.

Part 3: Factors in Using MET Inhibitors and When to Switch Inhibitors in NSCLC

During a live virtual event, Ravi Salgia, MD, PhD, discussed how to decide whether to use a MET inhibitor in the first line and whether to switch to a MET inhibitor from other treatments.

Part 2: Rare Mutations and Non-Clinical Barriers for Molecular Testing in NSCLC

During a live virtual event, Ravi Salgia, MD, PhD, discussed issues with molecular testing and biopsies including delays and affordability, plus identifying and responding to rare mutations detected by molecular testing.

Part 1: Practices for Molecular Testing to Determine Frontline Therapy in NSCLC

During a live virtual event, Ravi Salgia, MD, PhD, discussed a possible approach for biopsy and molecular testing of a patient diagnosed with lung adenocarcinoma.

Overview of MET Amplification and MET Exon 14 Skipping Mutations in NSCLC

Giuseppe Giaccone, MD, PhD, discusses alterations in the MET gene that can be oncogenic drivers in patients with non–small cell lung cancer.

Characteristics of the MET Exon 14 Skipping Mutation NSCLC Population

Mark A. Socinski, MD, discusses the patient population of the trials targeting MET exon 14 skipping mutations in non–small cell lung cancer.

The Relevance of MET Alterations to Targeted NSCLC Therapies

Martin Dietrich, MD, PhD, discusses the role MET alterations play as oncogenic drivers of non–small cell lung cancer.

Part 4: Whether to Switch Treatments After Discovery of MET Mutations in NSCLC

During a live virtual event, Martin Dietrich, MD, PhD, discusses how to address switching treatments in response to detection of a MET gene biomarker.

Part 3: Addressing Toxicities in MET Inhibitors for NSCLC

During a live virtual event, Martin Dietrich, MD, PhD, discusses management of toxicities and adverse events of MET inhibitors in non–small cell lung cancer.

Part 2: Choosing a Treatment for NSCLC with MET Exon 14 Skipping Mutation

At a live virtual event, Martin Dietrich, MD, PhD, discusses treatment options for a patient with non–small cell lung cancer when molecular testing shows a MET exon 14 skipping mutation.

Tepotinib Effective for MET+ NSCLC Found by Tissue or Liquid Biopsy

Giuseppe Giaccone, MD, PhD, discusses the results of the VISION trial of tepotinib in patients with non–small cell lung cancer.

Part 1: Challenges in Performing Biopsies and Molecular Testing in NSCLC

At a live virtual event, Martin Dietrich, MD, PhD, discusses how to approach biopsies and molecular testing in coordination with pathologists and testing services for patients with non–small cell lung cancer.